Navigation Links
Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
Date:11/14/2012

nt expenses are primarily costs relating to Palatin's Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for the treatment of FSD.

Cash Position
Palatin's cash and cash equivalents were $33.5 million as of September 30, 2012, compared to $3.8 million at June 30, 2012, with current liabilities of $1.6 million as of September 30, 2012 compared to $3.5 million as of June 30, 2012.

Palatin believes that its existing capital resources will be adequate to fund its currently planned operations, including completing analysis of results of the Company's Phase 2B clinical trial with bremelanotide for FSD, submitting an end-of-phase 2 meeting request to the FDA, and commencing Phase 3 activities, through at least calendar year 2013.

CONFERENCE CALL / WEBCAST Palatin will host a conference call and webcast on November 14, 2012 at 11:00 a.m. Eastern Time to discuss the results of operations and an update on corporate developments in greater detail.  Individuals interested in listening to the conference call live can dial 1-888-428-9490 (domestic) or 1-719-325-2354 (international), pass code 9649528.  The webcast and replay can be accessed by logging on to the "Investor/Media Center-Webcasts" section of Palatin's website at http://www.palatin.com.  A telephone and webcast replay will be available approximately one hour after the completion of the call.  To access the telephone replay, dial 1-888-203-1112 (domestic) or 1-719-457-0820 (international), pass code 9649528.  The webcast and telephone replay will be available through November 20, 2012. 

About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor- specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing co
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
3. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
4. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
5. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
6. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
7. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
8. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
9. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
10. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
11. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... ISPE announced today that ... the newly created position of Vice President of ... be responsible for stimulating ISPE’s revenue growth by ... Society’s Member-led and staff-driven business model, initiating integrated ... membership and product marketing. , “Barbara joins ISPE ...
(Date:5/16/2013)... 2013 In late 2012, Dr. Sarah Hart, ... doctors in China about Appearance Medicine . Although Dr. ... her first trip to lecture in China, and quite a ... Fuzhou, home to 12 and 7 million people respectively. Interest ... at this point in time. As Dr. Hart passed through ...
(Date:5/16/2013)... Cambridge Healthtech Institute will host its fifth annual ... Renaissance Waterfront Hotel in Boston, MA. The ten ... the current strategies and innovations for optimizing bioprocesses while ... the field will reveal how their work has resulted ... and efficiency. , “In this age of rapid innovation, ...
(Date:5/16/2013)...  HealthSparq, a trusted provider of healthcare transparency ... health plans, will debut a new benchmark study ... 2013 conference on June 13.  The presentation will ... insurance companies across the country are thinking about ... for increased healthcare transparency. This ...
Breaking Biology Technology:ISPE Names Barbara A. Myers, CAE, as Vice President of Professional Development 2The 2013 Bioprocessing Summit to Bring Together International Leaders to Discuss Today's Bioprocess Issues From Cell Line Selection to Manufacturing in Boston, MA 2HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013 2HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013 3
... - Oncothyreon Inc. (NASDAQ: ONTY ) (TSX: ONY) ... or $0.13 per basic and diluted share for the quarter ... $5.1 million or $0.26 per basic and diluted share for ... is primarily the result of the transfer of manufacturing activities ...
... - Bioniche Pharma, a leading developer and manufacturer ... (R) (edrophonium chloride injection, USP) and Enlon-Plus(R) ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080702/AQW070LOGO )"The acquisition and launch ... and a commitment to bringing this important therapy ...
... announced that Chief Executive Officer, Mitchell H. Gold, M.D., ... Of The Year (R) 2009 Award in the ... the awards program recognizes entrepreneurs who demonstrate extraordinary success ... commitment to their businesses and communities. Mitchell Gold ...
Cached Biology Technology:Oncothyreon reports first quarter 2009 financial results 2Oncothyreon reports first quarter 2009 financial results 3Oncothyreon reports first quarter 2009 financial results 4Oncothyreon reports first quarter 2009 financial results 5Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest 2
(Date:5/16/2013)... MA -- Injectable nanoparticles developed at MIT may ... 1 diabetes to constantly monitor their blood-sugar levels ... were designed to sense glucose levels in the ... of insulin, thereby replacing the function of pancreatic ... Type 1 diabetes. Ultimately, this type of system ...
(Date:5/16/2013)... May 16, 2013 Integrated Biometrics patented ... a custom thin film transistor camera introduces Sherlock, ... roll image in the smallest and lightest form ... Appendix F Mobile ID FAP 45, Certified scanner ... in size and weight when compared to optical ...
(Date:5/16/2013)... where the entirety of an individual,s DNA is examined ... can cause health problems is a massively useful technology ... major ethical problems if used incorrectly, say new recommendations ... on line today (16 May 2013) in the ... on whole genome and on exome* sequencing and analysis ...
Breaking Biology News(10 mins):Nanotechnology could help fight diabetes 2Nanotechnology could help fight diabetes 3European Society of Human Genetics urges caution over use of new genetic sequencing techniques 2
... , Contributing to the diversity of plant species (avoiding ... using examples of native flora preferably instead of exotic species ... landscaped areas are some of the recommendations town councils should ... is the opinion of Paloma Carianos Gonzlez , researcher ...
... the University of Pittsburgh could expand the options for ... to more than one type of antipsychotic drug. The ... cortex could be a promising target for developing future ... action. The study will be published during the week ...
... armed forces and intelligence community seek out strategies that ... fronts, University of Houston researchers are developing innovative techniques ... the homeland. That pairing of tactical and technical expertise ... third Department of Defense Research Conference. "UH researchers ...
Cached Biology News:Expert recommends town councils to design low-allergy impact green spaces 2Pitt research identifies new target in brain for treating schizophrenia 2Research conference at UH to focus on US troops' needs, homeland security 2
... The ISOQUANT(R) Isoaspartate Detection Kit is ... residues in proteins and peptides, which can ... asparagine or rearrangement of aspartic acid residues ... does not depend on the monitoring of ...
Request Info...
Rb anti-Occludin (C-term GST)...
Request Info...
Biology Products: